Is heparin effective in decreasing mortality among hospitalized patients with COVID-19?: Dr Vityala Yethindra

Dr. Vityala Yethindra is the World's youngest scientist in the medicine, a 12-time world record holder, and holding Guinness World record for "longest title of a book." He completed 51 courses in reputed universities, author of 2 books and 23 research articles in reputed journals. He received many national and international awards for his contributions to humanity and medical research.

Unfractionated Heparin (UFH) is used to prevent blood clotting in critically ill patients of coronavirus disease (COVID-19), but not in the case of pregnant women, who may develop venous thromboembolism (VTE).

Why does COVID-19 cause blood clotting?

In patients with COVID-19 after developing symptoms, the lungs are initially affected. The virus enters the body through breathing until it reaches the airways, and in some patients accompanied by an aggressive inflammatory response with the release of a large amount of pro-inflammatory cytokines called “Cytokine Storm.” This phenomenon causes an imbalance in the body and leads to thrombosis and these two mechanisms occur together, such as damage to the endothelium or widespread coagulation within blood vessels. As there is a chance of developing serious conditions UFH is used.

In severe cases, clinical signs of thrombosis develops in the body and patients are at greater risk of having serious conditions that involve obstruction of blood vessels in the heart, brain, and lungs. UFH works by preventing the formation of blood clots, known as thrombi.

Study of Dr. Vityala Yethindra and Tugolbai Tagaev’s team

What was this study objective?

In coagulopathy, COVID-19 is correlated with high mortality due to an increased concentration of D-dimers. This study aimed to elucidate the correlation between the anticoagulant therapy (ACT) with UFH and the mortality rate in hospitalized COVID-19 patients.

What are the methods followed?

The clinical records of 110 patients with COVID-19 admitted to the City Clinical Hospital No. 1 (Bishkek, Kyrgyzstan) until May 18, 2020, were reviewed. Patients with body temperature >37°C and SaO2 37°C and SaO2

Related News

Join NewsTrack Whatsapp group